Yannick Van Herck
Overview
Explore the profile of Yannick Van Herck including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
935
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hatse S, Lambrechts Y, Antoranz Martinez A, De Schepper M, Geukens T, Vos H, et al.
J Pathol
. 2024 Sep;
264(3):344-356.
PMID: 39344093
The impact of aging on the immune landscape of luminal breast cancer (Lum-BC) is poorly characterized. Understanding the age-related dynamics of immune editing in Lum-BC is anticipated to improve the...
2.
Mobaraki S, Nissen P, Donskov F, Wozniak A, Van Herck Y, Coosemans L, et al.
Clin Genitourin Cancer
. 2024 Aug;
22(5):102180.
PMID: 39155162
Background: Genetic variants of UGT1A1, involved in glucuronidation and clearance of bilirubin, are associated with reduced bilirubin metabolization and drug-induced isolated hyperbilirubinemia. We studied the impact of the UGT1A1*28 polymorphism...
3.
Beulque Y, Kinget L, Roussel E, Mobaraki S, Laenen A, Debruyne P, et al.
Acta Oncol
. 2024 Aug;
63:658-668.
PMID: 39129249
Background And Purpose: This study aims to evaluate neutrophil-to-eosinophil ratio (NER) as a prognostic and/or predictive biomarker in metastatic clear cell renal cell carcinoma (m-ccRCC) treated with nivolumab or ipilimumab/nivolumab....
4.
Neven P, Dullens L, Han S, Deblander A, Van Herck Y, Van Houdt M, et al.
Transl Breast Cancer Res
. 2024 May;
4:31.
PMID: 38751459
No abstract available.
5.
Pozniak J, Pedri D, Landeloos E, Van Herck Y, Antoranz A, Vanwynsberghe L, et al.
Cell
. 2024 Jan;
187(1):166-183.e25.
PMID: 38181739
To better understand intrinsic resistance to immune checkpoint blockade (ICB), we established a comprehensive view of the cellular architecture of the treatment-naive melanoma ecosystem and studied its evolution under ICB....
6.
Lamarthee B, Callemeyn J, Van Herck Y, Antoranz A, Anglicheau D, Boada P, et al.
Nat Commun
. 2023 Jul;
14(1):4359.
PMID: 37468466
Rejection remains the main cause of premature graft loss after kidney transplantation, despite the use of potent immunosuppression. This highlights the need to better understand the composition and the cell-to-cell...
7.
Naulaerts S, Datsi A, Borras D, Antoranz Martinez A, Messiaen J, Vanmeerbeek I, et al.
Sci Transl Med
. 2023 Apr;
15(691):eadd1016.
PMID: 37043555
Clinically relevant immunological biomarkers that discriminate between diverse hypofunctional states of tumor-associated CD8 T cells remain disputed. Using multiomics analysis of CD8 T cell features across multiple patient cohorts and...
8.
Ibanez-Molero S, van Vliet A, Pozniak J, Hummelink K, Terry A, Monkhorst K, et al.
Oncoimmunology
. 2022 Dec;
11(1):2139074.
PMID: 36465485
Immunotherapies, in particular immune checkpoint blockade (ICB), have improved the clinical outcome of cancer patients, although many fail to mount a durable response. Several resistance mechanisms have been identified, but...
9.
Malengier-Devlies B, Filtjens J, Ahmadzadeh K, Boeckx B, Vandenhaute J, De Visscher A, et al.
Front Immunol
. 2022 Oct;
13:861251.
PMID: 36275702
COVID-19 is characterised by a broad spectrum of clinical and pathological features. Natural killer (NK) cells play an important role in innate immune responses to viral infections. Here, we analysed...
10.
Karras P, Bordeu I, Pozniak J, Nowosad A, Pazzi C, Van Raemdonck N, et al.
Nature
. 2022 Oct;
611(7934):E4.
PMID: 36261534
No abstract available.